Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CombinatoRx to Present at the 2008 BioCentury Future Leaders in the Biotech Industry Conference.


CAMBRIDGE, Mass. -- CombinatoRx, Incorporated (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: CRXX) today announced that Alexis Borisy, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  is scheduled to present at the upcoming BioCentury Future Leaders Future Leaders is a UK schools-led charitable organisation that aims to widen the pool of talented leaders especially for urban challenging secondary schools. It was founded in March 2006 by Nat Wei, a former founder of Teach First.  in the Biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 Industry Conference at the Millennium Broadway Hotel. Mr. Borisy is scheduled to present on Thursday, March 27, 2008 at 10:00 AM ET. Interested parties may access a live webcast of the presentation by visiting the CombinatoRx website at www.combinatorx.com.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a trial results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation).
Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States.
. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 concerning CombinatoRx, its product candidates and their clinical potential, its plans for clinical and preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable.

pre·clin·i·cal
adj.
1.
 development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, risks associated with the preclinical development of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.


Form 10-K

See 10-K.
 on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2008 CombinatoRx, Incorporated. All rights reserved.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Conference notes
Date:Mar 20, 2008
Words:412
Previous Article:Pzena Investment Management, Inc. Announces 2008 Annual Meeting of Stockholders.
Next Article:RF Monolithics Reports Second Quarter Results.
Topics:



Related Articles
BioPartnering Europe (BPE) Features Informative Sessions on the Hottest Themes in Biotech Today.
Genitope Corporation to Present at Two Upcoming Investor Conferences in New York City: BioCentury's NewsMakers in the Biotech Industry and the Bear...
BioPartnering Europe (BPE) Lives up to Its Reputation as the Top European Biotech Event for Partnering as Number of Partnering Meetings Reaches...
Synta Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference on March 29, 2007.
CombinatoRx to Present at the Future Leaders in the Biotech Industry Investment Conference.
BioLineRx to Present at BioCentury's Future Leaders in the Biotech Industry Conference 2008.
BIO-Europe Spring(R) 2008 Program Shines a Light on Biotech Industry Developments in Spain.
Accentia Biopharmaceuticals to Present at BioCentury "Future Leaders in Biotech" Conference in New York.
GTx Announces Webcast of Corporate Presentation at the NewsMakers in the Biotech Industry Conference.
Exelixis Announces September 4 Webcast of Presentation at BioCentury's NewsMakers in the Biotech Industry Conference.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles